CA1305416C - Method of isolating ca 125 antigen - Google Patents

Method of isolating ca 125 antigen

Info

Publication number: CA1305416C
Authority: CA; Canada
Prior art keywords: antigen; species; fraction; sepharose; urea
Prior art date: 1986-11-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA000552637A

Other languages

English (en)

French (fr)

Inventor

Hugh M. Davis

Thomas L. Klug

Vincent R. Zurawski

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Janssen Biotech Inc

Original Assignee

Centocor Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-11-24

Filing date

1987-11-24

Publication date

1992-07-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25464497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA1305416(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1987-11-24 Application filed by Centocor Inc filed Critical Centocor Inc

1992-07-21 Application granted granted Critical

1992-07-21 Publication of CA1305416C publication Critical patent/CA1305416C/en

2009-07-21 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

108010008629 CA-125 Antigen Proteins 0.000 title claims abstract description 44
102000007269 CA-125 Antigen Human genes 0.000 title claims abstract description 44
238000000034 method Methods 0.000 title claims abstract description 40
241000894007 species Species 0.000 claims abstract description 30
230000000694 effects Effects 0.000 claims description 58
XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 52
229920002684 Sepharose Polymers 0.000 claims description 41
102000004169 proteins and genes Human genes 0.000 claims description 32
108090000623 proteins and genes Proteins 0.000 claims description 32
239000004202 carbamide Substances 0.000 claims description 30
206010033128 Ovarian cancer Diseases 0.000 claims description 27
150000001720 carbohydrates Chemical class 0.000 claims description 20
239000006228 supernatant Substances 0.000 claims description 20
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims description 18
239000002253 acid Substances 0.000 claims description 15
239000011347 resin Substances 0.000 claims description 14
229920005989 resin Polymers 0.000 claims description 14
230000003196 chaotropic effect Effects 0.000 claims description 12
238000001542 size-exclusion chromatography Methods 0.000 claims description 12
239000003795 chemical substances by application Substances 0.000 claims description 11
230000009257 reactivity Effects 0.000 claims description 11
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims description 10
239000000203 mixture Substances 0.000 claims description 10
239000002609 medium Substances 0.000 claims description 7
239000011800 void material Substances 0.000 claims description 7
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 6
238000003916 acid precipitation Methods 0.000 claims description 5
239000000872 buffer Substances 0.000 claims description 5
238000002270 exclusion chromatography Methods 0.000 claims description 4
230000002163 immunogen Effects 0.000 claims description 4
SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 3
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 3
PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims description 3
SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 3
OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims description 3
OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 3
MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims description 3
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 3
MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 3
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 3
239000000727 fraction Substances 0.000 claims description 3
229930182830 galactose Natural products 0.000 claims description 3
229950006780 n-acetylglucosamine Drugs 0.000 claims description 3
238000000502 dialysis Methods 0.000 claims description 2
LRPQMNYCTSPGCX-UHFFFAOYSA-N dimethyl pimelimidate Chemical compound COC(=N)CCCCCC(=N)OC LRPQMNYCTSPGCX-UHFFFAOYSA-N 0.000 claims description 2
239000001963 growth medium Substances 0.000 claims description 2
230000003472 neutralizing effect Effects 0.000 claims 3
GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims 1
FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims 1
239000003463 adsorbent Substances 0.000 claims 1
239000006143 cell culture medium Substances 0.000 claims 1
239000013628 high molecular weight specie Substances 0.000 claims 1
230000003053 immunization Effects 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
125000005629 sialic acid group Chemical group 0.000 claims 1
102000036639 antigens Human genes 0.000 abstract description 57
108091007433 antigens Proteins 0.000 abstract description 57
239000000427 antigen Substances 0.000 abstract description 56
210000004027 cell Anatomy 0.000 description 25
238000011282 treatment Methods 0.000 description 21
210000002966 serum Anatomy 0.000 description 19
206010028980 Neoplasm Diseases 0.000 description 17
235000014633 carbohydrates Nutrition 0.000 description 17
238000003556 assay Methods 0.000 description 14
235000020256 human milk Nutrition 0.000 description 14
210000004251 human milk Anatomy 0.000 description 14
238000003127 radioimmunoassay Methods 0.000 description 14
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 13
238000000746 purification Methods 0.000 description 13
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
239000002953 phosphate buffered saline Substances 0.000 description 12
201000011510 cancer Diseases 0.000 description 11
102000005744 Glycoside Hydrolases Human genes 0.000 description 10
108010031186 Glycoside Hydrolases Proteins 0.000 description 10
206010061535 Ovarian neoplasm Diseases 0.000 description 10
108091005804 Peptidases Proteins 0.000 description 10
239000004365 Protease Substances 0.000 description 10
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 9
230000000890 antigenic effect Effects 0.000 description 9
230000029087 digestion Effects 0.000 description 9
210000001519 tissue Anatomy 0.000 description 9
230000029936 alkylation Effects 0.000 description 8
238000005804 alkylation reaction Methods 0.000 description 8
238000004587 chromatography analysis Methods 0.000 description 8
239000012228 culture supernatant Substances 0.000 description 8
239000000463 material Substances 0.000 description 8
102000003886 Glycoproteins Human genes 0.000 description 7
108090000288 Glycoproteins Proteins 0.000 description 7
238000004458 analytical method Methods 0.000 description 7
238000004440 column chromatography Methods 0.000 description 7
238000010828 elution Methods 0.000 description 7
239000000499 gel Substances 0.000 description 7
238000003119 immunoblot Methods 0.000 description 7
230000003647 oxidation Effects 0.000 description 7
238000007254 oxidation reaction Methods 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
239000000126 substance Substances 0.000 description 7
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 6
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
238000001962 electrophoresis Methods 0.000 description 6
238000002955 isolation Methods 0.000 description 6
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 6
239000007790 solid phase Substances 0.000 description 6
229920000936 Agarose Polymers 0.000 description 5
102000015728 Mucins Human genes 0.000 description 5
108010063954 Mucins Proteins 0.000 description 5
239000003599 detergent Substances 0.000 description 5
229960004198 guanidine Drugs 0.000 description 5
230000035484 reaction time Effects 0.000 description 5
239000000523 sample Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
108010059712 Pronase Proteins 0.000 description 4
239000007983 Tris buffer Substances 0.000 description 4
150000001413 amino acids Chemical class 0.000 description 4
239000002131 composite material Substances 0.000 description 4
238000002298 density-gradient ultracentrifugation Methods 0.000 description 4
239000012153 distilled water Substances 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
150000002482 oligosaccharides Polymers 0.000 description 4
QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical compound S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 4
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
108090000317 Chymotrypsin Proteins 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241001529936 Murinae Species 0.000 description 3
108090000631 Trypsin Proteins 0.000 description 3
102000004142 Trypsin Human genes 0.000 description 3
239000013060 biological fluid Substances 0.000 description 3
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 3
229960002376 chymotrypsin Drugs 0.000 description 3
238000005194 fractionation Methods 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
238000009169 immunotherapy Methods 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
229920002401 polyacrylamide Polymers 0.000 description 3
239000012723 sample buffer Substances 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
239000012588 trypsin Substances 0.000 description 3
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
102000005348 Neuraminidase Human genes 0.000 description 2
108010006232 Neuraminidase Proteins 0.000 description 2
239000000020 Nitrocellulose Substances 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
239000008351 acetate buffer Substances 0.000 description 2
-1 alditol acetate Chemical class 0.000 description 2
ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 2
230000002494 anti-cea effect Effects 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000003638 chemical reducing agent Substances 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
229960003082 galactose Drugs 0.000 description 2
238000002523 gelfiltration Methods 0.000 description 2
230000012010 growth Effects 0.000 description 2
210000004408 hybridoma Anatomy 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
230000002637 immunotoxin Effects 0.000 description 2
239000002596 immunotoxin Substances 0.000 description 2
229940051026 immunotoxin Drugs 0.000 description 2
231100000608 immunotoxin Toxicity 0.000 description 2
229920001220 nitrocellulos Polymers 0.000 description 2
229920001542 oligosaccharide Polymers 0.000 description 2
229940117953 phenylisothiocyanate Drugs 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
210000000582 semen Anatomy 0.000 description 2
208000004548 serous cystadenocarcinoma Diseases 0.000 description 2
239000000243 solution Substances 0.000 description 2
AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 description 2
125000003396 thiol group Chemical group [H]S* 0.000 description 2
239000003104 tissue culture media Substances 0.000 description 2
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
238000005199 ultracentrifugation Methods 0.000 description 2
238000001262 western blot Methods 0.000 description 2
BSFODEXXVBBYOC-UHFFFAOYSA-N 8-[4-(dimethylamino)butan-2-ylamino]quinolin-6-ol Chemical compound C1=CN=C2C(NC(CCN(C)C)C)=CC(O)=CC2=C1 BSFODEXXVBBYOC-UHFFFAOYSA-N 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
238000011725 BALB/c mouse Methods 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
102000037716 Chondroitin-sulfate-ABC endolyases Human genes 0.000 description 1
108090000819 Chondroitin-sulfate-ABC endolyases Proteins 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
206010013457 Dissociation Diseases 0.000 description 1
102000002464 Galactosidases Human genes 0.000 description 1
108010093031 Galactosidases Proteins 0.000 description 1
102000002268 Hexosaminidases Human genes 0.000 description 1
108010000540 Hexosaminidases Proteins 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
208000007542 Paresis Diseases 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
241001632427 Radiola Species 0.000 description 1
101000916532 Rattus norvegicus Zinc finger and BTB domain-containing protein 38 Proteins 0.000 description 1
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
238000005852 acetolysis reaction Methods 0.000 description 1
238000010306 acid treatment Methods 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
102000012086 alpha-L-Fucosidase Human genes 0.000 description 1
108010061314 alpha-L-Fucosidase Proteins 0.000 description 1
DUKURNFHYQXCJG-JEOLMMCMSA-N alpha-L-Fucp-(1->4)-[beta-D-Galp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)[C@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](OC(O)[C@H](O)[C@H]3O)CO)O[C@H](CO)[C@@H]2O)O)O[C@@H]1CO DUKURNFHYQXCJG-JEOLMMCMSA-N 0.000 description 1
229910001870 ammonium persulfate Inorganic materials 0.000 description 1
230000003698 anagen phase Effects 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
239000011324 bead Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
238000009835 boiling Methods 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
244000309464 bull Species 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
244000309466 calf Species 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229940077731 carbohydrate nutrients Drugs 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
238000011097 chromatography purification Methods 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
229940009976 deoxycholate Drugs 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
208000018459 dissociative disease Diseases 0.000 description 1
239000012149 elution buffer Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
238000001641 gel filtration chromatography Methods 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
229930182470 glycoside Natural products 0.000 description 1
150000002338 glycosides Chemical class 0.000 description 1
102000035122 glycosylated proteins Human genes 0.000 description 1
108091005608 glycosylated proteins Proteins 0.000 description 1
239000011544 gradient gel Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000012510 hollow fiber Substances 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
230000002055 immunohistochemical effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000011503 in vivo imaging Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
FKADDOYBRRMBPP-UHFFFAOYSA-N lacto-N-fucopentaose II Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(C)=O)C(OC2C(C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C2O)O)OC1CO FKADDOYBRRMBPP-UHFFFAOYSA-N 0.000 description 1
239000010410 layer Substances 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
229940041290 mannose Drugs 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
239000007758 minimum essential medium Substances 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000004264 monolayer culture Methods 0.000 description 1
229940051875 mucins Drugs 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
208000012318 pareses Diseases 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
239000011148 porous material Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
239000000047 product Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
229940070376 protein Drugs 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000003643 water by type Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/832—Milk; colostrum
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/85—Reproductive organs or embryos
- Y10S530/852—Sperm
- Y10S530/853—Ovary; eggs; embryos

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Toxicology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Compounds Of Unknown Constitution (AREA)
Magnetic Heads (AREA)
Macromonomer-Based Addition Polymer (AREA)

CA000552637A 1986-11-24 1987-11-24 Method of isolating ca 125 antigen Expired - Lifetime CA1305416C (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US06/933,784 US5059680A (en)	1986-11-24	1986-11-24	Method of isolating ca 125 antigen
US933,784		1986-11-24

Publications (1)

Publication Number	Publication Date
CA1305416C true CA1305416C (en)	1992-07-21

Family

ID=25464497

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000552637A Expired - Lifetime CA1305416C (en)	1986-11-24	1987-11-24	Method of isolating ca 125 antigen

Country Status (7)

Country	Link
US (1)	US5059680A (de)
EP (1)	EP0332651B2 (de)
JP (1)	JPH02501258A (de)
AT (1)	ATE97448T1 (de)
CA (1)	CA1305416C (de)
DE (1)	DE3788229T3 (de)
WO (1)	WO1988003954A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE8901127D0 (sv) *	1989-03-31	1989-03-31	Aa H L Pousette	Reagenssats och dess anvaending foer att bilda (spap-anti-spap) -immunkomplex samt diagnostiskt foerfarand vid vilket spap detekteras
US5366866A (en) *	1991-07-25	1994-11-22	Duke University	Method of diagnosing ovarian and endometrial cancer with monoclonal antibodies OXA and OXB
US5976818A (en) *	1991-12-16	1999-11-02	The Board Of Trustees Of The University Of Arkansas	Monoclonal antibodies which identify the glycoprotein carrying the CA 125 epitope
US5800347A (en) *	1995-11-03	1998-09-01	The General Hospital Corporation	ROC method for early detection of disease
EP0957749A2 (de) *	1995-09-12	1999-11-24	The General Hospital Corporation	Verfahren zur früherkennung des eierstockrebs
US7318921B2 (en)	1996-05-15	2008-01-15	Altarex Medical Corp.	Therapeutic compositions that alter the immune response
US8038994B2 (en)	1996-05-15	2011-10-18	Quest Pharmatech Inc.	Combination therapy for treating disease
IL139700A (en)	1998-06-15	2005-09-25	Altarex Medical Corp	Immunotherapeutic composition for the treatment of prostate cancer
US6376654B1 (en)	1999-08-13	2002-04-23	Molecular Discoveries, Llc	Myeloma cell and ovarian cancer cell surface glycoproteins, antibodies thereto, and uses thereof
US7226750B1 (en)	2000-08-08	2007-06-05	Molecular Discoveries, Inc.	Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof
US7229780B2 (en)	2000-09-05	2007-06-12	The Medical Research Council	Monoclonal antibody against ovarian carcinoma
WO2004035537A2 (en)	2002-10-16	2004-04-29	Euro-Celtique S.A.	Antibodies that bind cell-associated ca 125/o772p and methods of use thereof
EP2261255A1 (de) *	2003-07-15	2010-12-15	The Regents of The University of California	Verfahren zur Reinigung von Sialinsäure-spezifischen Antikörpern und Zusammensetzung, die die affinitätsgereinigten Antikörper enthält
WO2013151649A1 (en)	2012-04-04	2013-10-10	Sialix Inc	Glycan-interacting compounds
FI3218005T3 (fi)	2014-11-12	2023-03-31	Seagen Inc	Glykaanin kanssa vuorovaikutteisia yhdisteitä ja käyttömenetelmiä
US9879087B2 (en)	2014-11-12	2018-01-30	Siamab Therapeutics, Inc.	Glycan-interacting compounds and methods of use
CA3002097A1 (en)	2015-11-12	2017-05-18	Siamab Therapeutics, Inc.	Glycan-interacting compounds and methods of use
WO2018094143A1 (en)	2016-11-17	2018-05-24	Siamab Therapeutics, Inc.	Glycan-interacting compounds and methods of use
WO2018160909A1 (en)	2017-03-03	2018-09-07	Siamab Therapeutics, Inc.	Glycan-interacting compounds and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2630380A1 (de) *	1975-07-14	1977-02-03	Microlog Ltd	Verfahren zur herstellung einer vakzine
US4584278A (en) *	1982-03-19	1986-04-22	University Of Rochester	Antigen derived from human ovarian tumors and radioimmunoassay using the antigen
JPS60256284A (ja) *	1984-06-01	1985-12-17	Nippon Telegr & Teleph Corp <Ntt>	動画像送受信方式

1986
- 1986-11-24 US US06/933,784 patent/US5059680A/en not_active Expired - Lifetime
1987
- 1987-11-20 EP EP87908082A patent/EP0332651B2/de not_active Expired - Lifetime
- 1987-11-20 WO PCT/US1987/003052 patent/WO1988003954A1/en not_active Ceased
- 1987-11-20 AT AT87908082T patent/ATE97448T1/de not_active IP Right Cessation
- 1987-11-20 JP JP63500323A patent/JPH02501258A/ja active Pending
- 1987-11-20 DE DE3788229T patent/DE3788229T3/de not_active Expired - Lifetime
- 1987-11-24 CA CA000552637A patent/CA1305416C/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JPH02501258A (ja)	1990-05-10
US5059680A (en)	1991-10-22
DE3788229T2 (de)	1994-04-21
EP0332651A1 (de)	1989-09-20
WO1988003954A1 (en)	1988-06-02
ATE97448T1 (de)	1993-12-15
EP0332651B2 (de)	1996-12-27
DE3788229T3 (de)	1997-04-10
DE3788229D1 (de)	1993-12-23
EP0332651B1 (de)	1993-11-18

Legal Events

Date	Code	Title	Description
2009-07-21	MKEX	Expiry

Publication	Publication Date	Title
CA1305416C (en)	1992-07-21	Method of isolating ca 125 antigen
Davis et al.	1986	Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas
Fuks et al.	1975	Carcinoembryonic antigen (CEA): Molecular biology and clinical significance
CA1183451A (en)	1985-03-05	Method for producing a csap tryptic peptide and anti- csap antibodies
Abe et al.	1989	Structural analysis of the DF3 human breast carcinoma-associated protein
Pancino et al.	1991	Purification and characterisation of a breast-cancer-associated glycoprotein not expressed in normal breast and identified by monoclonal antibody 83D4
JPS63279784A (ja)	1988-11-16	新ムチンエピトープに対する単クローン性抗体を生成するハイブリドーマ
Persson et al.	1982	Purification of a native membrane-associated adenovirus tumor antigen
Zhang et al.	1997	Comparison of sialyl-Lewis a-carrying CD43 and MUC1 mucins secreted from a colon carcinoma cell line for E-selectin binding and inhibition of leukocyte adhesion
US4269825A (en)	1981-05-26	New glycoprotein and process for isolating it
US4402872A (en)	1983-09-06	Protein and process for isolating it
Klug et al.	1988	Purification and composition of a novel gastrointestinal tumor-associated glycoprotein expressing sialylated lacto-N-fucopentaose II (CA 19-9)
Iacobelli et al.	1993	Purification and characterization of a 90 kDa protein released from human tumors and tumor cell lines
EP0351313A2 (de)	1990-01-17	Glycoprotein und dessen kodierendes Gen
EP0087898A1 (de)	1983-09-07	Antikörper und Antigene zur Bestimmung und Behandlung von Krebs
US4468345A (en)	1984-08-28	Protein (PP17), a process for concentrating and isolating it and its use
Katari et al.	1990	Characterization of the shed form of the human tumor-associated glycoprotein (TAG-72) from serous effusions of patients with different types of carcinomas
US4500451A (en)	1985-02-19	New protein PP13 extracted from human placental tissues and use thereof
HU208546B (en)	1993-11-29	Process for producing human antibodies for treating non-small-cell pulmonary-carcinomes, hib ridomes producing them, and antigenes recognised by the antibodies, and diagnostical process and kit
US4746731A (en)	1988-05-24	Isolated tissue protein PP18
Seya et al.	1987	Additional forms of human decay-accelerating factor (DAF).
Shuichi et al.	1986	Purification and characterization of IgE produced by human myeloma cell line, U266
Van Munster et al.	1969	Evidence of immunochemical differences between free and bound secretory piece
US5773215A (en)	1998-06-30	Tumor marker protein for cancer risk assessment
Pfeffer et al.	1986	Biosynthesis of spectrin and its assembly into the cytoskeletal system of Friend erythroleukemia cells.